-
AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
The US Food and Drug Administration (FDA) approved a new therapy for the best-selling anti-cancer drug Imfinzi from British pharmaceutical giant AstraZeneca on Thursday (August 15th). According to me ... -
Baidu Health Platform has attracted over 300000 doctors to join and serve over 210 million patients
On July 19th, at the 2024 Baidu Health Industry Ecology Conference held in Beijing, He Mingke, Senior Vice President of Baidu Group and President of Baidu Big Health Business Group, delivered a keyno ... -
American brain computer company pioneers: Empowering patients with communication skills through OpenAI models
Last week, Synchron, an American brain computer interface (BCI) company, announced the integration of OpenAI's artificial intelligence model into the chat function of its BCI platform, providing user ... -
Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
Southern Finance and Economics, May 13 (Xinhua) - Zaiding Pharmaceutical Hong Kong Stock Exchange announced that the National Medical Products Administration of China has approved the use of reprotin ... -
The latest research: Wegovy is also effective for patients with diabetes and heart failure
A new study shows that Wegovy (mainly composed of smeglutide), the "weight-loss magic drug" of Novo Nordisk, can not only lose weight, but also benefit the health of patients with diabetes and heart ... -
Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
On March 6th local time, the US Food and Drug Administration (FDA) approved Pfizer's BESPONSA& Reg; (Oxytozumab) is used to treat children aged 1 year and above with relapsed or refractory precursor ... -
Federal Reserve Governor Waller: Stay patient with interest rate cuts, wait for more data!
Federal Reserve Governor Christopher Waller said on Thursday that the surge in consumer prices in January requires careful decision-making on when to begin rate cuts, although he still expects them t ... -
Li Xiande from Jingke Energy: Maintain strategic patience during the industry's lowest period of downturn. Unprofitable production capacity will be quickly phased out
Among the photovoltaic giants, Li Xiande, the chairman of Jingke Energy, may be an alternative. Even during the peak of the industry, he rarely appears in the spotlight and is very low-key. On Januar ...